X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15995) 15995
Book Review (3111) 3111
Publication (832) 832
Newsletter (626) 626
Newspaper Article (123) 123
Magazine Article (121) 121
Conference Proceeding (109) 109
Book Chapter (62) 62
Transcript (20) 20
Trade Publication Article (17) 17
Dissertation (7) 7
Web Resource (5) 5
Data Set (3) 3
Presentation (3) 3
Reference (3) 3
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (12981) 12981
humans (12742) 12742
warfarin (10815) 10815
male (6923) 6923
female (6600) 6600
anticoagulants - administration & dosage (5480) 5480
aged (5113) 5113
warfarin - administration & dosage (4971) 4971
middle aged (4634) 4634
anticoagulants (4348) 4348
anticoagulants - therapeutic use (3871) 3871
anticoagulants - adverse effects (3505) 3505
warfarin - therapeutic use (3395) 3395
administration, oral (3058) 3058
atrial fibrillation (3034) 3034
risk factors (2919) 2919
adult (2901) 2901
warfarin - adverse effects (2817) 2817
abridged index medicus (2665) 2665
stroke (2600) 2600
cardiac & cardiovascular systems (2345) 2345
pharmacology & pharmacy (2309) 2309
aged, 80 and over (2298) 2298
international normalized ratio (2253) 2253
treatment outcome (2201) 2201
atrial fibrillation - drug therapy (2112) 2112
anticoagulation (2094) 2094
dosage and administration (2089) 2089
hematology (2057) 2057
prevention (2007) 2007
therapy (1999) 1999
peripheral vascular disease (1991) 1991
dabigatran (1869) 1869
hemorrhage - chemically induced (1854) 1854
medicine, general & internal (1838) 1838
thromboembolism (1744) 1744
drug therapy (1687) 1687
stroke - prevention & control (1672) 1672
risk (1660) 1660
management (1650) 1650
retrospective studies (1585) 1585
care and treatment (1506) 1506
atrial-fibrillation (1505) 1505
atrial fibrillation - complications (1483) 1483
rivaroxaban (1354) 1354
thrombosis (1312) 1312
analysis (1301) 1301
research (1297) 1297
drug interactions (1291) 1291
time factors (1266) 1266
aspirin (1207) 1207
dose-response relationship, drug (1176) 1176
thromboembolism - prevention & control (1168) 1168
medicine & public health (1132) 1132
surgery (1121) 1121
venous thromboembolism (1116) 1116
animals (1087) 1087
hemorrhage (1073) 1073
health aspects (1047) 1047
complications and side effects (973) 973
patients (970) 970
stroke - etiology (960) 960
warfarin - pharmacology (951) 951
prospective studies (947) 947
follow-up studies (899) 899
safety (881) 881
prothrombin time (871) 871
blood coagulation - drug effects (868) 868
apixaban (867) 867
cardiac arrhythmia (863) 863
stroke prevention (856) 856
bleeding (842) 842
risk assessment (842) 842
mortality (831) 831
drug administration schedule (828) 828
cardiology (826) 826
antithrombotic therapy (783) 783
pharmacogenetics (764) 764
thrombin (759) 759
pharmacokinetics (758) 758
vitamin k - antagonists & inhibitors (758) 758
oral anticoagulants (741) 741
usage (741) 741
anticoagulants - pharmacology (739) 739
heparin (724) 724
internal medicine (717) 717
drug therapy, combination (716) 716
oral anticoagulation (704) 704
adolescent (693) 693
medical research (681) 681
anticoagulants - pharmacokinetics (673) 673
warfarin - pharmacokinetics (665) 665
genotype (663) 663
molecular-weight heparin (661) 661
clinical trials (633) 633
complications (624) 624
metaanalysis (619) 619
heparin - administration & dosage (616) 616
cyp2c9 (614) 614
risk-factors (613) 613
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16161) 16161
Japanese (195) 195
French (98) 98
Russian (93) 93
German (90) 90
Spanish (66) 66
Swedish (37) 37
Norwegian (35) 35
Chinese (29) 29
Italian (23) 23
Danish (17) 17
Hungarian (17) 17
Turkish (14) 14
Czech (13) 13
Polish (9) 9
Portuguese (9) 9
Hebrew (7) 7
Korean (7) 7
Finnish (5) 5
Croatian (3) 3
Dutch (2) 2
Serbian (2) 2
Bulgarian (1) 1
Georgian (1) 1
Lithuanian (1) 1
Persian (1) 1
Romanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies | Index Medicus
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 06/2016, Volume 5, Issue 6, p. n/a
Journal Article
by Schulman, Sam and Kakkar, Ajay K and Goldhaber, Samuel Z and Schellong, Sebastian and Eriksson, Henry and Mismetti, Patrick and Christiansen, Anita Vedel and Friedman, Jeffrey and Le Maulf, Florence and Peter, Nuala and Kearon, Clive and Schulman, S and Eriksson, H and Goldhaber, S and Kakkar, A and Kearon, C and Mismetti, P and Schellong, S and Bergqvist, D and Tijssen, J and Prins, M. [=Martin H.] and Robben, S and Büller, H and Otten, H. M and Brandjes, D and Peters, R and Mac Gillavry, M. R and Gan, E and Salem, H and Baker, R and Blomberry, P and Curnow, J and Annichino-Bizzacch, J. M and Brandao Panico, M. D and Timi Ribas, J. R and Fernandes Manenti, E. R and Miranda, F and Moraes, J and Raev, D and Mollov, M and Peneva, M and Milanov, S and Anderson, D and Crowther, M and Dolan, S and Eikelboom, J and Game, M and Kahn, S and Kassis, J and Ritchie, B and Solymoss, S and Rodger, M and Yeo, E and Milot, A and Klinke, P and Chen, W and Zhihong, L and Chunxue, B and Jinming, L and Jiwei, Z and Jie, C and Jina, K and Yuqi, W and Zhongqi, Y and Hua, W and Kejing, Y and Bonan, L and Yadong, Y and Changwei, L and Jin, Z and Yongcheng, D and Spinar, J and Maly, R and Cizek, V and Bercikova, J and Cervinka, P and Lang, P and Jirka, V and Oral, I and Reichert, P and Kotik, L and Pojsl, S and Klimovic, T and Husted, S and Nielsen, H and Friis, E and Skødebjerg Kristensen, K and Mottier, D and El Kouri, D and Bleher, Y and Leroux, L and Boda, Z and Sereg, M and Riba, M and Hiremath, J. S and Kareem, S and Banker, D. N and Gadkari, M and Parakh, R and Suresh, K. R and ... and RE-COVER II Trial Investigators
Circulation, ISSN 0009-7322, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Index Medicus | Abridged Index Medicus | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, pp. e100478 - e100478
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9745, pp. 975 - 983
Summary Background Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of... 
Internal Medicine | INTENSITY | MEDICINE, GENERAL & INTERNAL | ORAL ANTICOAGULANT-THERAPY | METAANALYSIS | OUTCOMES | FREQUENCY | Anticoagulants - administration & dosage | Humans | Middle Aged | Warfarin - adverse effects | Male | Dabigatran | Warfarin - administration & dosage | Warfarin - therapeutic use | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Thromboembolism - prevention & control | Adult | Female | Stroke - mortality | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | International Normalized Ratio | Stroke - etiology | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Prevention | Complications and side effects | Warfarin | Atrial fibrillation | Anticoagulants (Medicine) | Dosage and administration | Research | Comparative analysis | Drug therapy | Risk factors | Fees & charges | Studies | Stroke | Mortality | Data collection | Grants | Clinical medicine | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Journal of Nephrology, ISSN 1121-8428, 12/2014, Volume 27, Issue 6, pp. 659 - 666
The novel iron-based phosphate binder sucroferric oxyhydroxide is being investigated for the treatment of hyperphosphatemia. Patients with chronic kidney... 
Nephrology | Phase I | Medicine & Public Health | Urology/Andrology | Hyperphosphatemia | Chronic kidney disease | Pharmacokinetics | Sucroferric oxyhydroxide | MORTALITY | PHOSPHORUS | PHOSPHATE BINDER | BIOAVAILABILITY | INDIVIDUALS | DIALYSIS PATIENTS | PA21 | CALCIUM | UROLOGY & NEPHROLOGY | HEMODIALYSIS | CHRONIC KIDNEY-DISEASE | Digoxin - adverse effects | Diuretics - pharmacokinetics | Chelating Agents - administration & dosage | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Warfarin - administration & dosage | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Cardiotonic Agents - adverse effects | Diuretics - blood | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Diuretics - administration & dosage | Risk Assessment | Furosemide - pharmacokinetics | Cardiotonic Agents - pharmacokinetics | Omeprazole - administration & dosage | Sucrose - adverse effects | Anticoagulants - adverse effects | Anticoagulants - blood | Cardiotonic Agents - administration & dosage | Models, Biological | Ferric Compounds - adverse effects | Losartan - administration & dosage | Diuretics - adverse effects | Furosemide - administration & dosage | Angiotensin II Type 1 Receptor Blockers - adverse effects | Anticoagulants - administration & dosage | Area Under Curve | Losartan - blood | Omeprazole - blood | Warfarin - adverse effects | Ferric Compounds - administration & dosage | Healthy Volunteers | Furosemide - adverse effects | Adult | Female | Proton Pump Inhibitors - blood | Digoxin - blood | Losartan - pharmacokinetics | Chelating Agents - adverse effects | Furosemide - blood | Sucrose - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Models, Statistical | Digoxin - pharmacokinetics | Warfarin - pharmacokinetics | Proton Pump Inhibitors - pharmacokinetics | Digoxin - administration & dosage | Cardiotonic Agents - blood | Warfarin - blood | Losartan - adverse effects | Anticoagulants - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - blood | Drug Combinations | Index Medicus | Original
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2015, Volume 128, Issue 12, pp. 1300 - 1305.e2
Journal Article
European Heart Journal, ISSN 0195-668X, 07/2014, Volume 35, Issue 28, pp. 1873 - 1880
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | NETWORK | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | METAANALYSIS | RISK | THERAPY | WARFARIN | ASSOCIATION | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article